UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Designer receptor technology for the treatment of epilepsy

Lieb, A; Weston, M; Kullmann, DM; (2019) Designer receptor technology for the treatment of epilepsy. EBioMedicine , 43 pp. 641-649. 10.1016/j.ebiom.2019.04.059. Green open access

[thumbnail of Kullmann_Designer receptor technology for the treatment of epilepsy_VoR.pdf]
Preview
Text
Kullmann_Designer receptor technology for the treatment of epilepsy_VoR.pdf

Download (2MB) | Preview

Abstract

Epilepsy remains refractory to medical treatment in ~30% of patients despite decades of new drug development. Neurosurgery to remove or disconnect the seizure focus is often curative but frequently contraindicated by risks of irreversible impairment to brain function. Novel therapies are therefore required that better balance seizure suppression against the risks of side effects. Among experimental gene therapies, chemogenetics has the major advantage that the action on the epileptogenic zone can be modulated on demand. Two broad approaches are to use a designer G-protein-coupled receptor or a modified ligand gated ion channel, targeted to specific neurons in the epileptogenic zone using viral vectors and cell-type selective promoters. The receptor can be activated on demand by either an exogenous compound or by pathological levels of extracellular glutamate that occur in epileptogenic tissue. We review the principal designer receptor technologies and their modes of action. We compare the drawbacks and benefits of each designer receptor with particular focus on the drug activators and the potential for clinical translation in epilepsy.

Type: Article
Title: Designer receptor technology for the treatment of epilepsy
Location: Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ebiom.2019.04.059
Publisher version: https://doi.org/10.1016/j.ebiom.2019.04.059
Language: English
Additional information: © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Chemogenetics, DREADD, Designer receptor, GluCl, PSAM, hM4D(Gi)
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Clinical and Experimental Epilepsy
URI: https://discovery.ucl.ac.uk/id/eprint/10074997
Downloads since deposit
57Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item